PMC:7696151 / 22721-23009
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 656 | 109-112 | Chemical | denotes | HCQ | MESH:D006886 |
| 661 | 129-146 | Disease | denotes | viremia reduction | MESH:D007022 |
| 662 | 210-219 | Disease | denotes | infection | MESH:D007239 |
| 663 | 275-287 | Disease | denotes | inflammation | MESH:D007249 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T25 | 129-136 | Phenotype | denotes | viremia | http://purl.obolibrary.org/obo/HP_0020071 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T159 | 0-288 | Sentence | denotes | Therefore, considering the results obtained from these clinical studies, it is possible to say that although HCQ does not affect viremia reduction, as demonstrated by the lack of activity in the first phase of infection, it can improve the chronic phase diseases by reducing inflammation. |